New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCJC-1295 vs Thymagen

CJC-1295 vs Thymagen

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
CJC-1295
Immune Support
Thymagen
Summary
CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
Thymagen is a dipeptide bioregulator (Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the thymus gland. It supports T-lymphocyte maturation, thymic function, and immune system normalization. As the thymus involutes with age (thymic atrophy), immune competence declines. Thymagen is used to support immune restoration, particularly in aging, post-illness recovery, and immunodeficiency states.
Half-Life
~30 minutes (No DAC) / 6–8 days (with DAC)
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
100 mcg
10 mg per day
Frequency
Once daily, before bed
Daily for 10–30 days
Key Benefits
  • Sustained increase in growth hormone levels
  • Enhanced muscle growth and strength
  • Improved fat metabolism and body composition
  • Better recovery and tissue repair
  • Increased bone density
  • Enhanced immune function
  • Improved skin quality and collagen production
  • Synergistic GH release when combined with GHRPs like Ipamorelin
  • Supports thymic epithelial cell function and T-cell maturation
  • May partially restore thymic output reduced by age-related atrophy
  • Normalizes T-lymphocyte subpopulation balance
  • Supports immune recovery after illness, surgery, or chemotherapy
  • Anti-aging effects on thymic tissue
  • Complementary to Thymosin Alpha-1 and Thymalin in immune protocols
  • May improve vaccine responsiveness in older individuals
Side Effects
  • Water retention / puffiness
  • Carpal tunnel syndrome (with prolonged use)
  • Injection site irritation
  • Hunger increase (minor)
  • +1 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant immunological adverse events reported
Stacks With